Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study
Public DepositedRelations
- Parents:
This work has no parents.
Items
Thumbnail | Title | Date Uploaded | Visibility | Actions |
---|---|---|---|---|
1465-9921-15-78.pdf | 2019-05-06 | Public | Download | |
Prohibited medications prior to Visit 1, by time interval. Table S2. Summary of ECG abnormalities meeting the withdrawal criteria. Table S3. Summary of Holter abnormalities meeting the withdrawal criteria. | 2019-05-06 | Public | Download |